The 14th Five-Year Plan of Guangzhou International Bio Island (2021-25) was recently released. It is a plan to bolster the island as a national pilot zone for biomedicine policy innovation as well as a world leading biomedicine and biosafety R&D center.
An industrial layout that focuses on biomedicine R&D, medical examination and testing, stem cells and regenerative medicine, and high-end medical equipment will take shape. This layout will be complemented with medical information services and health management.
The construction of major projects including Bioland Lab, Bio-Thera Solutions' R&D headquarters, Luye Life Sciences Group's regenerative medicine headquarters and innovation research institution, and a large scientific research facility for human cell lineage, will be pushed forward.
A rendering of the Bioland Lab.
World-class innovation and achievement transformation platforms for respiratory diseases will be established on the Guangzhou International Bio Island. High-level science and technology talents as well as innovation and entrepreneurship teams will be attracted from around the globe.
The international cooperation with Europe and the Israel in the biomedicine sector will be deepened. The cooperation mechanism within the Guangdong-Hong Kong-Macao Greater Bay Area will be improved.
An aerial photo of Guangzhou International Bio Island.
By 2025, a set of management and operation systems conducive to the characteristic development of biomedicine industry will be aligned with an efficient public service system for local enterprises.
The futuristic island is projected to be China's first demonstration park for the application of 5G autonomous driving with the promotion of WeRide's Robobuses, unmanned sweeping cars, and other intelligent projects.